PARIS & NEW YORK, May 17, 2016 (GLOBE NEWSWIRE) -- Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company developing new therapies for unmet medical needs in the field of cardiovascular diseases, today announced that the United States Patent and Trademark Office (USPTO) issued two U.S. Patents (No. 9,340,497 and No. 9,278,921) pertaining to the Company’s lead investigational drug candidate, QGC001, a first-in-class Brain Aminopeptidase A Inhibitor (BAPAI).
The claims of the first granted patent (No. 9,340,497) cover the crystalline trihydrate form of QGC001, which is currently being evaluated in a Phase 2 trial for the treatment of hypertension. To date, related applications have been granted in China, Japan, Israel, New Zealand, Mexico, the Russian Federation and South Africa. Patent applications for similar claims are pending in Europe and in many other countries, including Brazil, Canada, South Korea and India. The patent is valid through November 2031, and could be extended by up to five years under the Drug Price Competition and Patent Term Restoration Act, depending on the approval of a new drug application (NDA).
The second patent (No. 9,278,921) issued by the USPTO claims a new crystalline phase of QGC001 with L-lysine and its use for the treatment of hypertension and heart failure. This patent is valid through October 2033, and its expiration date could also be extended by up to five years.
Lionel Segard, Quantum Genomics’ President and Chief Executive Officer, commented, “We are pleased that the USPTO has issued these two patents for our lead candidate, QGC001. They are important additions to our intellectual property portfolio. These patents further strengthen the protection of QGC001 and its use for the treatment of hypertension and heart failure in one of our major markets, potentially until 2038.”
ABOUT QUANTUM GENOMICS
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially hypertension and heart failure.
The Company is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.
Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC).
The Company has offices in Paris, France, and New York, NY, USA. For more information, please visit www.quantum-genomics.com.
CONTACTS Quantum Genomics Lionel Ségard Chairman & Chief Executive Officer +33 1 85 34 77 77 Quantum Genomics Marc Karako CFO – Investor Relations +33 1 85 34 77 75 email@example.com ACTUS finance et communication (Europe) Jean-Michel Marmillon Press Relations +33 1 53 67 36 73 firstname.lastname@example.org The Ruth Group (U.S.) Lee Roth / Kirsten Thomas Investor / Public Relations +1 646-536-7012 / +1 508-280-6592